Home › NDC Lookup › Ingredients › Losartan Potassium › 65862-0203-90
⚪image loading
(from DailyMed)

Losartan Potassium 100 mg Tablet, Film Coated, 90-count — NDC 65862-203-90 (Billing 65862-0203-90)

by Aurobindo Pharma Limited · 90 TABLET, FILM COATED in 1 BOTTLE

This is a package of 90 tablets of Losartan Potassium 100 mg Tablet, Film Coated from Aurobindo Pharma Limited, marketed since Oct 2010 and currently FDA-listed; retail pharmacies pay about $0.0445 per tablet (NADAC).

NDC 65862-0203-90
🏷️ FDA NDC (as labeled) 65862-203-90 billing pads the product segment with a zero
This package
Contains90-count Cost per ea$0.0445 NADAC Per package$4.01 / 90 tablets Pack sizes4 compare ↓
Also priced by: Medicaid pays $0.2184/unit · Part D plans $0.1027/unit — full pricing hub ↓
Product page 65862-0203-99 Also comes in: 30 tablets 65862-203-30 1000 tablets 65862-203-99 2000 tablets 65862-203-22
On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Oct 1, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 65862-203-90
Product NDC 65862-203
11-digit billing NDC 65862020390
NCPDP billing unit EA — each (per item)
SPL Set ID 8393ee97-a1ec-48de-ad40-2b3a0244585a
DEA schedule Non-controlled
Marketing category DRUG FOR FURTHER PROCESSING
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2010-10-06
Dosage form TABLET, FILM COATED
Substance LOSARTAN POTASSIUM

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 36150040200340
GPI class Losartan Potassium
GCN Seq No 038686
GCN 14853
HICL code 009829
Ingredient (HICL) Losartan Potassium
HIC1 code A
Therapeutic class — broad (HIC1) Cardiovascular System
HIC2 code A4
Therapeutic class — intermediate (HIC2) Antihypertensives
HIC3 code A4F
Therapeutic class — specific (HIC3) Antihypertensives, Angiotensin Receptor Antagonist
AHFS code 24:32.08.00
AHFS class Angiotensin Ii Receptor Antagonists
FDB label name LOSARTAN POTASSIUM 100 MG TAB
FDB brand name Losartan Potassium
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 038686
  • GCN: 14853
  • GPI-14 (Medi-Span): 36150040200340
  • HICL (First Databank): 009829
  • AHFS class code: 24:32.08.00
Why two NDCs? The FDA registers this code as 65862-203-90 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 65862-0203-90. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

Label name LOSARTAN POTASSIUM 100 MG TAB Ingredient Losartan Potassium
📗 Our plain-language guide HelloPharmacist
  • Losartan is used mainly to treat high blood pressure in adults and children 6 and older. It's also used to lower the risk of stroke in people who have high blood pressure and an en...
  • Cough is much less common with losartan than with ACE inhibitors (like lisinopril). In clinical trials, the rate of cough with losartan was similar to that seen with a placebo. So...
  • Does losartan cause a cough like some other blood pressure medicines?
  • It's best to check with your doctor or pharmacist first. NSAIDs like ibuprofen and naproxen can reduce how well losartan controls your blood pressure, and they can also put extra s...
📖 Read our full Losartan guide →
1
Nutrient depletion considerations

Losartan Potassium may be associated with lower levels of 1 nutrient — worth a chat with your pharmacist, not a cause for alarm.

🧪 Full Losartan Potassium nutrient depletion report →
An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.045 $4.01 / 90 tablets
Medicaid paysCMS SDUD · 12 mo $0.2184 $19.66 / 90 tablets
Medicare drug plans payPart D · Q2 2026 $0.1027 $9.24 / 90 tablets
NADAC price history (per ea) — tap or hover for the price & month
Jan 2022 Aug 2022 Jan 2026 Sep 2026 $0.105 $0.041
▼ Down 50% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
65862-0203-30 65862-203-30 30 TABLET, FILM COATED in 1 BOTTLE $0.0445 / ea $1.34 2010-10-06 — Active
65862-0203-90 You're viewing this 90 TABLET, FILM COATED in 1 BOTTLE $0.0445 / ea $4.01 2010-10-06 — Active
65862-0203-99 65862-203-99 Main listing 1000 TABLET, FILM COATED in 1 BOTTLE $0.0445 / ea $44.53 2010-10-06 — Active
65862-0203-22 65862-203-22 2000 TABLET, FILM COATED in 1 BAG — — — — Active

You're viewing one of 4 pack sizes for this product.

This pack effectively ties for the lowest per-ea cost of the 3 priced pack sizes ($0.0445 NADAC).

This pack accounts for about 5.4% of this product's recent Medicaid fills; most go to the 1000 tablets pack. See all packs ↓

Pack size FAQ

What quantity is in this package?
This is a 90-count package — 90 tablet, film coated in 1 bottle.
How does this package differ from NDC 65862-0203-30?
Both are Losartan Potassium 100 mg Tablet, Film Coated — the drug itself is identical. This page's package is the 90-count one, while NDC 65862-0203-30 is the 30 tablets package.
What NDC number is used to bill for this package of Losartan Potassium 100 mg Tablet, Film Coated?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
LOSARTAN POTASSIUM 100 mg 64380-0935-04 Strides 30 tablets $0.044 AB Availability likely save 1%
Losartan Potassium 100 mg 00904-7049-61 Major 1 tablet $0.045 AB Availability likely —
Losartan Potassium 100 mg 11788-0102-10 AiPing 1000 tablets $0.045 AB Availability likely —
Losartan potassium 100 mg 33342-0046-07 Macleods 30 tablets $0.045 AB Availability likely —
Losartan Potassium 100 mg 43547-0362-03 Solco 30 tablets $0.045 AB Availability likely —
Losortan Potassium 100 mg 50268-0506-15 AvPAK 1 tablet $0.045 AB Availability likely —
Losartan Potassium 100 mg 62332-0029-30 Alembic 30 tablets $0.045 AB Availability likely —
Losartan Potassium 100 mgthis 65862-0203-90 Aurobindo 90 tablets $0.045 — Availability likely —
Losartan Potassium 100 mg 68084-0348-01 American 1 tablet $0.045 AB Availability likely —
Losartan Potassium 100 mg 70010-0743-03 Granules 30 tablets $0.045 AB Availability likely —
Losartan potassium 100 mg 72205-0143-30 Novadoz 30 tablets $0.045 AB Availability likely —
Losartan Potassium 100 mg 72603-0342-01 NorthStar 90 tablets $0.045 AB Availability likely —
Losartan Potassium 100 mg 82009-0044-10 Quallent 1000 tablets $0.045 AB Availability likely —
Losartan Potassium 100 mg 42571-0112-10 Micro 1000 tablets $0.056 AB Discontinued +25%
Cozaar 100 mg 78206-0123-01 Organon 30 tablets $6.140 AB Availability likely +13688%
Losartan Potassium 100 mg 00615-7960-05 NCS 15 tablets — AB FDA listed —
Losartan Potassium 100 mg 29300-0146-01 Unichem 100 tablets — AB FDA listed —
Losartan Potassium 100 mg 31722-0702-05 Camber 500 tablets — AB FDA listed —
Losartan Potassium 100 mg 43063-0954-30 PD-Rx 30 tablets — AB FDA listed —
Losartan Potassium 100 mg 46708-0447-30 Alembic 30 tablets — AB FDA listed —
Losartan Potassium 100 mg 50090-3403-00 A-S 90 tablets — AB FDA listed —
Losartan Potassium 100 mg 50090-4712-00 A-S 90 tablets — AB FDA listed —
Losartan Potassium 100 mg 50090-4914-00 A-S 90 tablets — AB FDA listed —
Losartan Potassium 100 mg 51655-0791-26 Northwind 90 tablets — AB FDA listed —
Losartan Potassium 100 mg 51655-0828-26 Northwind 90 tablets — AB FDA listed —
Losartan Potassium 100 mg 55154-2333-00 Cardinal 1 tablet — AB FDA listed —
Losartan Potassium 100 mg 55154-6643-00 Cardinal 1 tablet — AB FDA listed —
Losartan potassium Tablets, 100 mg 59746-0335-01 Jubilant 100 tablets — AB FDA listed —
Losartan Potassium 100 mg 62207-0743-49 Granules 1000 tablets — AB FDA listed —
Losortan Potassium 100 mg 63187-0072-30 Proficient 30 tablets — AB FDA listed —
Losartan Potassium 100 mg 63187-0708-30 Proficient 30 tablets — AB FDA listed —
Losartan Potassium 100 mg 63187-0808-30 Proficient 30 tablets — AB FDA listed —
Losartan potassium Tablets, 100 mg 63629-2428-01 Bryant 1000 tablets — AB FDA listed —
Losartan Potassium 100 mg 65841-0731-01 Zydus 100 tablets — AB FDA listed —
Losartan Potassium 100 mg 67046-0702-03 Coupler 30 tablets — AB FDA listed —
Losartan potassium Tablets, 100 mg 67046-1511-03 Coupler 30 tablets — AB FDA listed —
LOSARTAN POTASSIUM 100 mg 68071-2203-09 NuCare 90 tablets — AB FDA listed —
Losartan Potassium 100 mg 68071-2216-03 NuCare 30 tablets — AB FDA listed —
Losartan Potassium 100 mg 68071-2344-03 NuCare 30 tablets — AB FDA listed —
Losartan Potassium 100 mg 68071-3846-03 NuCare 30 tablets — AB FDA listed —
Losartan Potassium 100 mg 68071-5181-09 NuCare 90 tablets — AB FDA listed —
Losartan Potassium 100 mg 68180-0378-01 Lupin 100 tablets — AB FDA listed —
Losartan Potassium 100 mg 68382-0137-01 Zydus 100 tablets — AB FDA listed —
Losartan Potassium 100 mg 68788-8186-01 Preferred 100 tablets — AB FDA listed —
Losartan Potassium 100 mg 70518-0718-00 REMEDYREPACK 30 tablets — AB FDA listed —
Losartan potassium 100 mg 70518-4289-00 REMEDYREPACK 30 tablets — AB FDA listed —
Losartan Potassium 100 mg 71335-1235-01 Bryant 30 tablets — AB Discontinued —
Losartan Potassium 100 mg 71335-1580-01 Bryant 30 tablets — AB FDA listed —
Losartan Potassium 100 mg 71335-2083-01 Bryant 30 tablets — AB FDA listed —
Losartan Potassium 100 mg 71610-0083-30 Aphena 30 tablets — AB FDA listed —
Losartan Potassium 100 mg 71610-0465-30 Aphena 30 tablets — AB FDA listed —
Losartan potassium Tablets, 100 mg 72162-1698-00 Bryant 1000 tablets — AB FDA listed —
Losartan Potassium 100 mg 72162-2508-00 Bryant 1000 tablets — AB FDA listed —
Losartan Potassium 100 mg 72189-0097-30 Direct_Rx 30 tablets — AB FDA listed —
Losartan Potassium 100 mg 72789-0044-30 PD-Rx 30 tablets — AB FDA listed —
LOSARTAN POTASSIUM 100 mg 72789-0165-90 PD-Rx 90 tablets — AB FDA listed —
Losartan Potassium 100 mg 72865-0143-10 XLCare 1000 tablets — AB FDA listed —
losartan potassium 100 mg 60312-0960-00 ORGANON 97000 tablets — — FDA listed —
Losartan Potassium 100 mg 70518-4695-00 REMEDYREPACK 100 tablets — AB FDA listed —
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2010
On the market since
Oct 2010
📍
2026
Currently FDA-listed
16 years listed
🔓
·
Generic versions listed
see equivalents
✅Generic appears available

FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available — see Therapeutic equivalents.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerAurobindo Pharma Limited
Labeler code65862
First marketedOct 2010
Product typeDrug For Further Processing
Portfolio1,456 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full FDA label FDA SPL

The complete FDA label for this product, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📄 FDA label
📄 FDA label 19 words ▾

No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
32.5K
Units reimbursed last 4 qtrs
1.6M
Gross reimbursed last 4 qtrs
$359.7K
Avg / prescription
$11.06
Avg / unit
$0.2184
Latest quarter Q1 2026
7.3KRx
Medicaid pays / ea
$0.2184
gross reimbursed
vs
NADAC / ea
$0.0445
acquisition cost
=
Spread
+$0.1739
+391% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
53% FFS 47% MCO
Fee-for-service · 17,307 Rx Managed care · 15,206 Rx
State Medicaid map
Alaska: 510 units · 69.6 per 100k residents AK Maine: no data reported ME Washington: 29,440 units · 377 per 100k residents WA Idaho: 10,959 units · 558 per 100k residents ID Montana: 18,901 units · 1,670 per 100k residents MT North Dakota: no data reported ND Minnesota: 17,329 units · 302 per 100k residents MN Wisconsin: 20,992 units · 355 per 100k residents WI Michigan: 63,609 units · 634 per 100k residents MI New York: 398,121 units · 2,034 per 100k residents NY Vermont: 4,494 units · 695 per 100k residents VT New Hampshire: 748 units · 53.4 per 100k residents NH Oregon: 24,774 units · 585 per 100k residents OR Nevada: 2,119 units · 66.3 per 100k residents NV Wyoming: no data reported WY South Dakota: 2,191 units · 238 per 100k residents SD Iowa: 7,546 units · 235 per 100k residents IA Illinois: 39,481 units · 315 per 100k residents IL Indiana: 12,931 units · 188 per 100k residents IN Ohio: 67,780 units · 575 per 100k residents OH Pennsylvania: 85,121 units · 657 per 100k residents PA New Jersey: 36,827 units · 396 per 100k residents NJ Massachusetts: 2,955 units · 42.2 per 100k residents MA California: 347,847 units · 893 per 100k residents CA Utah: 1,410 units · 41.3 per 100k residents UT Colorado: 13,756 units · 234 per 100k residents CO Nebraska: 4,459 units · 225 per 100k residents NE Missouri: 28,894 units · 466 per 100k residents MO Kentucky: 49,279 units · 1,089 per 100k residents KY West Virginia: 30,382 units · 1,716 per 100k residents WV Virginia: 37,182 units · 427 per 100k residents VA Maryland: 50,145 units · 811 per 100k residents MD Connecticut: 12,058 units · 333 per 100k residents CT Rhode Island: no data reported RI Arizona: 4,979 units · 67.0 per 100k residents AZ New Mexico: 10,026 units · 474 per 100k residents NM Kansas: 534 units · 18.2 per 100k residents KS Arkansas: 8,362 units · 273 per 100k residents AR Tennessee: 15,234 units · 214 per 100k residents TN North Carolina: 20,471 units · 189 per 100k residents NC South Carolina: 2,267 units · 42.2 per 100k residents SC Delaware: 2,533 units · 246 per 100k residents DE Oklahoma: 12,770 units · 315 per 100k residents OK Louisiana: 13,699 units · 299 per 100k residents LA Mississippi: 781 units · 26.6 per 100k residents MS Alabama: 840 units · 16.4 per 100k residents AL Georgia: 4,726 units · 42.9 per 100k residents GA D.C.: 12,990 units · 1,913 per 100k residents DC Hawaii: 4,198 units · 293 per 100k residents HI Texas: 16,028 units · 52.5 per 100k residents TX Florida: 17,567 units · 77.7 per 100k residents FL
Units reimbursed · per 100k residents
16.42,034
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 New York 2,034 /100k
2 D.C. 1,913 /100k
3 West Virginia 1,716 /100k
4 Montana 1,670 /100k
5 Kentucky 1,089 /100k
6 California 893 /100k
7 Maryland 811 /100k
8 Vermont 695 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
1000 tablets65862-0203-99 563,478 Rx · $6,158,482
90 tablets this page65862-0203-90 32,513 Rx · $359,670
30 tablets65862-0203-30 9,879 Rx · $92,463
2000 tablets65862-0203-22 No Medicaid data
Drug total (last 4 qtrs): 605,870 Rx · 29,143,466 units · $6,610,614 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Losartan Potassium (matched by generic name) — the program that covers self-administered drugs. 20 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Losartan Potassium. CMS lists 3 products for this generic; we show the highest-spend one. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$87.55M
Claims incl. refills
9.7M
Beneficiaries
7.6M
Spend / beneficiary
$11.46
Spend / claim
$8.99
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

About this NDC listing & data coverage

Listed for further processing / repackaging

What "drug for further processing" means

FDA lists this package under the "drug for further processing" marketing category: Aurobindo Pharma Limited supplies it to other companies for further processing or repackaging (blister cards that are later repackaged or co-packaged are a common example). The units themselves are a finished dosage form — which is why pricing or Medicaid data can still appear — but this exact package code may not be the presentation a retail pharmacy dispenses.

What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos — Not published for this NDC No photo available yet for this listing.
Inactive ingredients (structured) — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available.
NADAC pharmacy acquisition price (CMS) ✓ Available
Orange Book / therapeutic-equivalence data — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope.
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) ✓ Available
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Is this NDC FDA-approved?
An NDC listing does not by itself establish FDA approval — the NDC Directory records that a product is listed with FDA, not that it was reviewed and approved. This listing's marketing category is "Drug For Further Processing". Products approved under an application carry an NDA, ANDA, or BLA number.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Aurobindo Pharma Limited. Listing status can change — the directory data on this page refreshes weekly.
Does this product come in other package sizes?
Yes — the FDA directory lists 3 other package presentations of this same product, including 30 tablets (65862-0203-30), 1000 tablets (65862-0203-99), 2000 tablets (65862-0203-22). Each has its own NDC and its own page — see the package list near the top of this page.
Who lists this product with the FDA?
Aurobindo Pharma Limited is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
← 65862-0202-30 · Aurobindo 65862-0204-37 · Aurobindo →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.